About ProMetic
ProMetic Life Sciences Inc. is a long established publicly traded (TSX symbol: PLI, OTCQX: PFSCF), biopharmaceutical corporation with a globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics. ProMetic is also active in developing its own novel therapeutics products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer, and autoimmune disease/inflammation as well as certain nephropathies. ProMetic’s business is organized into two distinct operating segments; Protein Technologies and Therapeutics, supported by a Head Office in Laval, Canada, R&D facilities in the UK, the USA and Canada as well as manufacturing facilities in the UK and business development activities in the USA, Europe and Asia.
Therapeutics
| Orally active PBI-1402 | Hematology – New Chemical Entities (NCEs) | Oncology – New Chemical Entities (NCEs) |
|---|---|---|
|
Advancing in clinical trials for the treatment of anemia:
|
|
|
Protein Technologies
| Prion Capture Technology | Bioseparation Products | Human Plasma-derived Therapeutics |
|---|---|---|
|
|
|